reported* the biological properties of a new substance, 4-isobutylphenyl acetic acid (Ibufenac). As assessed by the ultra-violet erythema test in guineapigs (Adams and Cobb, 1958) , it proved to have two to four times the anti-inflammatory effect of aspirin, and its analgesic activity as measured by a modification of the method of Randall and Selitto (1957) was of the same order. Their work suggested that this substance might be a useful substitute for acetylsalicylic acid. In human subjects, after doses of 640 mg. by mouth, detectable amounts were present in the blood within 30 to 60 minutes, rising to a maximum of 2 to 4 mg./100 ml. in 2 to 4 hours, and small but detectable amounts were still present 8 hours after ingestion of the dose (Adams, 1963) . Chalmers (1963) reported that Ibufenac in doses of 30 gr. daily appeared to be as effective as aspirin in doses of 60 gr. daily in the control of symptoms in patients with rheumatoid arthritis, side-effects being fewer with Ibufenac than with acetylsalicylic acid. Tudhope (1964) , using the 51chromium technique previously employed by Scott, Porter, Lewis, and Dixon (1961) and Wood, Harvey-Smith, and Dixon (1962) with salicylates, found Ibufenac considerably less productive of gastro-intestinal haemorrhage, the majority of patients showing no signs of significant bleeding on this drug. It seemed that here was a likely non-toxic substitute for aspirin which could be effectively used in half the dose in patients intolerant of that drug. However, the appearance of five cases of jaundice (Morton, 1964) An additional reason increasing, indirectly, the importance of Ibufenac is that, although hepatotoxicity may limit its obvious clinical value, there is a possibility of the development of analogues.
Material and Methods
In 62 patients with rheumatoid arthritis who were treated with Ibufenac, the sheep cell agglutination titre was positive between 1:32 and 1:130,000 in 39 and negative in 23; 21 patients were admitted to hospital and 41 were seen at fortnightly or monthly intervals in the out-patient clinic. The daily dose varied between 6 and 15 tablets each containing 250 mg. Ibufenac; 49 patients received twelve tablets daily, three received fifteen, six received eight, and four received six tablets daily. Most patients received 2 to 4 weeks' therapy but in certain instances long-term treatment was continued. By March, 1964, 25 patients had received continuous therapy for longer than 3 months, the longest period of administration being 17 months.
Progress in the condition of in-patients was assessed by daily record of pain, stiffness, and morning limberingup time, with twice-weekly records of joint size, strength of grip, joint tenderness, and erythrocyte sedimentation rate (Westergren). Ibufenac and an identical placebo were administered in turn and any alteration in the above criteria of assessment was noted.
The out-patients may be conveniently divided into three groups:
Sixteen patients were assessed at each visit by the same subjective parameters as those used in the ward and were asked to compare the effect noted after taking Ibufenac with the degree of symptomatic improvement obtained from paracetamol or aspirin on a tablet for tablet basis.
In thirteen patients, chosen because of the presence of measurable joint soft-tissue swelling, the joint size, grip strength, joint tenderness, and erythrocyte sedimentation rates were also measured.
The remaining twelve out-patients took part in a double-blind cross-over study, comparing the effect of Ibufenac, twelve 250-mg. tablets daily, with that of soluble aspirin, twelve 300-mg. tablets daily. These patients received each drug for 14 days and were assessed fully. Results
None of the 46 patients, consisting of 21 inpatients, twelve out-patients in the double-blind study, and thirteen out-patients in whom objective criteria were measured and in whom joint size was assessed regularly, exhibited significant reduction in joint swelling as a result of treatment with Ibufenac.
Of the twelve patients who received Ibufenac 3 g. daily and aspirin 3-6 g. daily, double-blind, seven preferred Ibufenac and five aspirin.
In twelve of the remaining fifty patients the symptomatic improvement on Ibufenac was considered to be better than that obtained with aspirin, fifteen out of the fifty noted improvement in pain and stiffness comparable to the effect of aspirin, and eighteen preferred aspirin in the doses employed. The early development of dyspepsia in five patients prevented the assessment of Ibufenac; in the other six patients, side-effects developed sufficiently slowly for assessment of therapeutic effect to be made. Of seventeen patients who also made a comparison with paracetamol (in 500-mg. tablets), sixteen preferred Ibufenac and only one preferred paracetamol for symptomatic relief.
Long-term therapy with Ibufenac has been continued in 25 patients for 3 months or longer; the actual duration of therapy is recorded in Table I . No apparent tolerance has been noted in this group, but evidence of abnormal hepatic function has The patient who developed jaundice was a man aged 57 who had had rheumatoid arthritis for 23 years and in whom the sheep cell agglutination titre (S.C.A.T.) was positive 1:1024. He took Ibufenac 3 g. daily for 4j months with moderate symptomatic improvement and without side-effects, but he then developed malaise, lassitude, and anorexia with occasional vomiting, flatulence, and retching, which continued for a fortnight and was followed by generalized itching and jaundice. The patient had a history of a moderately high intake of alcohol over a period of years. There was firm nontender hepatomegaly, and the signs of gross long-standing rheumatoid arthritis. Investigations indicated hepatocellular damage and a liver biopsy revealed the nonspecific changes of a mild hepatitis, and this patient was therefore considered to be suffering from Ibufenacinduced jaundice. Two features of note were the serial bilirubin and transaminase estimations during his stay in hospital. For 10 days, while still receiving Ibufenac after the onset of symptoms, the serum total bilirubin rose from 6 to 10-2 mg. per cent., and this was followed by a fall to 3-7 mg. per cent. during the fortnight after Ibufenac was stopped. During the 10 days of continued therapy the S.G.O.T. fell from 1,245 to 392 units and the S.G.P.T. from 704 to 257 units. In the absence of cholestasis in the liver biopsy, the rise in serum bilirubin probably represents hepato-cellular damage. Liver function tests and serum transaminase estimations in this patient returned to normal within 3 months of the development of jaundice which was present clinically for about 5 weeks.
Dyspepsia occurred in eight patients but was severe in two only (Table III (Table IV) . This is a selected group of patients in that those with intolerance to salicylates tended to be treated with Ibufenac. Other side-effects from aspirin included tinnitus in two cases and heavy perspiration. A patient who suffered from Meniere's syndrome was also unable to take salicylates. All these patients tolerated a full dosage with Ibufenac without sideeffects, as did two who were intolerant ofparacetamol. Barium meals were performed on four patients (Table V) . In one patient with dyspepsia from Ibufenac, salicylates, and phenylbutazone, the barium meal was normal. In two patients with peptic ulcers both intolerant of soluble aspirin, no dyspepsia followed the administration of Ibufenac. A patient with a hiatus hernia experienced no sideeffects from Ibufenac but was intolerant of both salicylates and phenylbutazone.
Discussion
On the published clinical evidence (Chalmers, 1963) and the result of this trial, it seems that Ibufenac is an effective aspirin substitute. In doses half those of acetylsalicylic acid it provides comparable relief of painful symptoms and seems to be less irritant to the gastro-intestinal tract. The evidence that the drug is hepato-toxic in man rests on five patients out of over 750 (Morton, 1964) who developed jaundice while taking the drug. Liver biopsies in our patient with jaundice and in one other revealed no diagnostic changes, the histological picture being that of non-specific hepatitis. The main problem lies in the interpretation of the significance of the rise in S.G.O.T. which appeared in about 20 to 30 per cent. of subjects from all centres taking the drug continuously for several months (Morton, 1964) . If the rise in serum transaminases reflects early liver damage consistently, then it may be possible to make this a screening test to detect patients who will develop jaundice. If this is so, liver damage may be expected to occur in about 20 to 30 per cent. of patients receiving the drug on a long-term basis. Such has not been our experience to date. The alternative possibilities are that the rise in serum transaminases may represent a transient alteration in hepatic function, or that it may derive from other sources and possess no particular significance. It should be noted in considering hepato-toxicity that, in the patient with Ibufenac-induced jaundice, during the phase of increasing liver damage with progressive elevation of the serum bilirubin, the serum transaminases gradually fell in spite of continued administration of the drug. In the group on long-term therapy, five out of six patients with raised serum transaminases were subsequently found to have normal or minimally elevated levels. In the sixth patient the S.G.O.T. rose to over 80 units for longer than 3 months but no other evidence of liver damage developed. In one patient only was there a rise in the S.G.P.T., an unexpected finding if the S.G.O.T. were of hepatic origin.
The transaminase enzymes are widely distributed in various tissues and occur, in significant concentration, in brain and cardiac muscle in addition to liver. A rise in S.G.O.T. occurs not only after myocardial infarction (Karmen, 1955) and as a result of liver disease (Wroblewski and LaDue, 1955) , but also in such disorders as dermatomyositis, polymyositis, and muscular dystrophy (Mellick and Bassett, 1964) ; it has also been reported after the administration of morphine, salicylates, chlorpromazine, and alcohol (Wroblewski, 1959) . Raised S.G.O.T. has also been reported in patients suffering from cardiac failure without infarction (Fragge, Kopel, and Iglauer, 1960; West, Gelb, Pilz, and Zimmerman, 1961) , and recently with status asthmaticus (ElShaboury, Thomas, and Williams, 1964) . It also follows severe exercise (Remmers and Kaljot, 1963) and has been reported during administration of the chloroquine derivative Amopyroquin (Bartholomew and Duff, 1963) . Serum transaminase elevation occurs in almost all patients receiving the anabolic steroids methyltestosterone, norethandrolone, and methandrolone (Wynn, Landon, and Kawerau, 1961 L'ict&re survint dans cette serie chez un sur 62 malades atteints d'arthrite rhumatismale et traites par Ibufenac et chez moins d'un pour cent de tous les malades traites jusqu'a present; tous se sont r6tablis completement. Le taux s6iique de transaminase augmenta chez 7 sur 25 malades soumis a un traitement prolonge et pendant que ce traitement continuait ce taux redevint normal chez 5 sur 6 d'entre eux. On pense que cette anomalie n'est pas toujours un signe sp-cifique d'une lesion hepatique. D'autres recherches sur l'hepato-toxicit6 de ce produit sont indiqu,es, car sa valeur clinique est evidente.
Ibufenac (acido 4-isobutilfenil acetico) SUMARIO Ibufenac (Acido 4-isobutilfenil acetico) es un substituto efectivo de la aspirina a la mitad de su dosis y se ve tolerado por muchos enfermos que padecen de dispepsia cuando toman salicilatos.
Una ictericia ocurri6 en esta serie en uno de los 62 enfermos con artritis reumatoide tratados con Ibufenac y en menos de uno por ciento de todas los enfermos tratados hasta la fecha; todos estan completamente restablecidos. Las cifras sericas de transaminasa subieron en 7 de los 25 enfermos tratados a termino largo al proseglir el tratamiento estas cifras volvieron a lo normal en 5 de 6 enfermos. Se sugiere que esta anomalia no es siempre una indicaci6n especifica de lesi6n hepatica. Investigaciones ulteriores sobre la hepato-toxicidad de este producto se ven indicadas, ya que su valor clinico es evidente.
